Cancer IO’s new report Cancer Immunotherapies in Finland was published in Helsinki University Think Corner on 9 March 2022.
The objective of the report is to provide understanding of the current state of the adoption and use of IO therapies in Finland compared to the other Nordics countries, and the factors affecting it.
The report includes the description of the processes involved in the adoption of new cancer treatments, and the financing and procurement of medicines in Finland and the Nordics.
The report is based on expert interviews with clinicians and hospital management, representatives of the pharmaceutical industry, and regulatory authorities/national bodies. The report focuses on the Finnish environment, but also briefly describes the similarities and differences of medicine evaluation, financing, and procurement processes between the Nordic countries.
The report includes Cancer IO’s recommendations on how to move forward with IO treatments while ensuring cost-effective use and quick access to new medicines with equity for patients across regions and diseases.